CBIO - NASDAQ

Crescent Biopharma, Inc.

CBIO·NASDAQ

$18.45

+8.5%

HealthcareBiotechnology

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$508.70M

EPS-14.7800

P/E Ratio-1.25

Earnings Date07/30/2026

cbio

Net Change in Cash

Last Annual Value

178.53M

3-Year CAGR

84%

5-Year CAGR

60%

10-Year CAGR

37%

Adjust for Inflation

Crescent Biopharma, Inc. Competitors Analysis of Net Change in Cash

CBIO · NASDAQ

Company	Net Change in Cash	CAGR 3Y	CAGR 5Y	CAGR 10Y
Crescent Biopharma, Inc. NASDAQ:CBIO	178.53M	N/A	N/A	N/A
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS	18.36M	N/A	-25.2%	N/A
Anixa Biosciences, Inc. NASDAQ:ANIX	-27.00K	N/A	N/A	N/A
Cardiff Oncology, Inc. NASDAQ:CRDF	-34.00M	N/A	N/A	N/A
Greenwich LifeSciences, Inc. NASDAQ:GLSI	2.09M	N/A	N/A	N/A
PepGen Inc. NASDAQ:PEPG	11.09M	N/A	-38.4%	N/A
Tevogen Bio Holdings Inc. NASDAQ:TVGN	230.60K	N/A	-49.6%	N/A
Armata Pharmaceuticals, Inc. AMEX:ARMP	-693.00K	N/A	N/A	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	-22.47M	N/A	N/A	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	19.10M	-41.8%	N/A	N/A
Heron Therapeutics, Inc. NASDAQ:HRTX	2.85M	-40.2%	N/A	N/A

Crescent Biopharma, Inc. Fair Value Envelope

CBIO · NASDAQ

Our analysis suggests that CBIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $18.45, this represents a potential HIDDEN relative to our calculated worth for Crescent Biopharma, Inc..

HIDDEN

Intrinsic Value

Current Price: $18.45

Related Guides

Blog Categories

Continue your CBIO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.